Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992420 · ClinicalTrials.gov registry record
Genotype Information and Functional Testing Study
A clinical trial of Coronary Artery Disease, sponsored by Scripps Health.
- Completed
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT00992420: Completed study of Coronary Artery Disease, sponsored by Scripps Health.
NCT00992420 is a study of Coronary Artery Disease that has completed, run by Scripps Health. The registered enrollment target is 2,000 participants, above the 1,278-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (56% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00992420, a study of Coronary Artery Disease, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
Primary Outcome
Outcome 1 is residual platelet reactivity the measurement
Conditions Studied
Study Locations (1)
California
- Scripps Genomic Medicine - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2009-10-01 |
| Est. Completion | 2010-08-31 |
What the finished NCT00992420 record still lists
NCT00992420 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,278-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (56% higher).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00992420 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00992420 about?
NCT00992420 is a clinical study titled "Genotype Information and Functional Testing Study". This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet ...
What is the current status of trial NCT00992420?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2009-10-01. Estimated completion is 2010-08-31.
What conditions does trial NCT00992420 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
Who is sponsoring clinical trial NCT00992420?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00992420 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00992420's enrollment target sits among peer trials
2,000 30th of 219 higher than 190 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI